{
  "slug": "clinical-features-and-outcomes-of-treatment-for-effusive-felin-41901790",
  "source": {
    "title": "Clinical Features and Outcomes of Treatment for Effusive Feline Infectious Peritonitis with GS-441524 in Seventeen Retrovirus-Positive Cats.",
    "journal": "Pathogens (Basel, Switzerland)",
    "year": 2026,
    "doi": "10.3390/pathogens15030337",
    "pmid": "41901790",
    "content_access_status": "FULL_TEXT_OA"
  },
  "claims": [
    {
      "statement": "This study collected survey data from caretakers of FeLV- and/or FIV-positive cats treated with GS-441524 for presumptive effusive FIP.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "98",
      "evidence_excerpt": "A survey was distributed to caretakers of cats with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV) that were treated with GS-441524 for presumptive effusive FIP based on survey responses.",
      "review_status": "PASSED"
    },
    {
      "statement": "In the reported cohort, the average starting GS-441524 dosage was 7 mg/kg/day, with dosage increases in 65% of cats and treatment extension in 35%.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "98",
      "evidence_excerpt": "The average starting dosage (7 mg/kg/d) was increased in 65% of cats, and treatment was extended in 35%.",
      "review_status": "PASSED"
    },
    {
      "statement": "Among the 17 retrovirus-positive cats with presumptive FIP, three cats relapsed, twelve-week survival was 94% (16/17), and one-year survival was 82% (14/17).",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "99",
      "evidence_excerpt": "Three cats relapsed (18%). There was a 94% (16/17) twelve-week survival rate and 82% (14/17) one-year survival rate.",
      "review_status": "NEEDS_HUMAN"
    },
    {
      "statement": "Seven cats were alive at follow-up a median of 1306 days after FIP diagnosis, while many cats died from neoplasia.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "98",
      "evidence_excerpt": "Seven cats were alive at follow-up, a median of 1306 days (range 983-2069) after FIP diagnosis, but many cats succumbed to neoplasia.",
      "review_status": "NEEDS_HUMAN"
    },
    {
      "statement": "The authors considered treatment success in retrovirus-positive cats with presumptive FIP similar to previously reported outcomes for FIP alone, while noting protocol and product limitations.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "97",
      "evidence_excerpt": "Treatment success for retrovirus-positive cats with presumptive FIP was similar to previously reported outcomes for FIP alone. This could support current evidence of successful antiviral therapy for similar populations, if noncurrent, unstandardized protocols and unlicensed product use are considered.",
      "review_status": "NEEDS_HUMAN"
    },
    {
      "statement": "Additional studies are needed to determine ideal protocols and the impact of FeLV proviral load in retrovirus-positive cats with FIP.",
      "epistemic_type": "OPEN_QUESTION",
      "evidence_level": null,
      "confidence": "99",
      "evidence_excerpt": null,
      "review_status": "PASSED"
    }
  ],
  "provenance": {
    "agent": "AVAPROJECT-VIROLOGY-001",
    "critic": "AVAPROJECT-CRITIC-001",
    "model": "openai-codex",
    "updated": "2026-08-31 19:46 UTC",
    "updated_iso": "2026-08-31T19:46:31Z"
  }
}